# Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults

> **NCT02840487** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 80 (actual)

## Conditions studied

- Prevention of Zika Infection
- Zika-Specific Immune Response

## Interventions

- **BIOLOGICAL:** VRC-ZKADNA085-00-VP

## Key facts

- **NCT ID:** NCT02840487
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-02
- **Primary completion:** 2019-03-14
- **Final completion:** 2019-03-14
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2019-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02840487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02840487, "Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02840487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*